Put Options

15 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$42.43 - $70.83 $492,188 - $821,628
-11,600 Reduced 29.74%
27,400 $1.87 Million
Q2 2024

Aug 14, 2024

BUY
$41.33 - $74.26 $913,393 - $1.64 Million
22,100 Added 130.77%
39,000 $1.65 Million
Q1 2024

May 15, 2024

SELL
$56.27 - $73.77 $123,794 - $162,294
-2,200 Reduced 11.52%
16,900 $1.17 Million
Q4 2023

Feb 14, 2024

SELL
$59.06 - $75.72 $366,172 - $469,464
-6,200 Reduced 24.51%
19,100 $1.41 Million
Q3 2023

Nov 14, 2023

SELL
$65.94 - $99.04 $204,414 - $307,024
-3,100 Reduced 10.92%
25,300 $1.73 Million
Q2 2023

Aug 14, 2023

BUY
$62.68 - $95.05 $607,996 - $921,985
9,700 Added 51.87%
28,400 $2.67 Million
Q1 2023

May 15, 2023

BUY
$47.19 - $70.77 $637,065 - $955,395
13,500 Added 259.62%
18,700 $1.27 Million
Q4 2022

Feb 14, 2023

SELL
$30.35 - $53.15 $971,200 - $1.7 Million
-32,000 Reduced 86.02%
5,200 $257,000
Q3 2022

Nov 14, 2022

BUY
$31.97 - $49.37 $1.19 Million - $1.84 Million
37,200 New
37,200 $1.21 Million
Q2 2020

Aug 14, 2020

SELL
$55.75 - $92.75 $602,100 - $1 Million
-10,800 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$37.9 - $104.44 $234,980 - $647,528
-6,200 Reduced 36.47%
10,800 $626,000
Q4 2019

Feb 14, 2020

BUY
$77.66 - $99.74 $823,196 - $1.06 Million
10,600 Added 165.63%
17,000 $1.57 Million
Q3 2019

Nov 14, 2019

BUY
$90.37 - $122.49 $18,074 - $24,498
200 Added 3.23%
6,400 $578,000
Q2 2019

Aug 14, 2019

BUY
$89.51 - $118.04 $152,167 - $200,668
1,700 Added 37.78%
6,200 $732,000
Q1 2019

May 15, 2019

BUY
$61.98 - $96.5 $278,910 - $434,250
4,500 New
4,500 $390,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $9.36B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.